X
CAD
$1000,395,000
CannTrust
BOUGHT DEAL, JUNE 2018
TRANSACTIONS
OUR TRANSACTIONS HELP IDENTIFY, FOSTER AND CREATE INVESTMENT OPPORTUNITIES IN THE HEALTHCARE SECTOR, ON BEHALF OF COMPANIES AND INVESTORS
FILTER BY
>
Service
>
Sector
>
Stage
>
X
CDN $55,000,000
Satellos Bioscience Inc.
PUBLIC OFFERING
MAY 2023
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body's innate muscle repair and regeneration process. The Company's lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario.
X
Juno Pharmaceuticals Canada
M&A ADVISORY, DEBT FINANCING
MAY 2023
Juno Pharmaceuticals Canada specializes in manufacturing, developing, and delivering high-quality, cost-effective, complex, and high value generic, branded and biosimilar products. With operations in Toronto and Montreal, Juno is one of the largest generic injectable businesses in Canada with domestic manufacturing capabilities and a robust distribution pipeline throughout 22 international markets. An early member of the global Juno Pharmaceuticals group, Juno’s global operations span four continents and consist of over 14 diverse pharmaceutical and medical device businesses spread across Canada, the United Kingdom, the European Union, Australia, and South Africa.
X
CDN $1,453,000
NeuPath Health
PRIVATE PLACEMENT
MAY 2023
NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. The company operates a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual the company treats to live their best life.
X
CDN $85,000,000*
Miravo Healthcare
M&A ADVISORY
MARCH 2023
*Enterprise Value
Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada, though the Company is in the process of winding-down its manufacturing operations in Varennes.
X
CDN $1,500,000
BetterLife Pharma Inc.
PRIVATE PLACEMENT
MARCH 2023
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.
X
CDN $27,200,000
Mimi's Rock Corp.
M&A ADVISORY
FEBRUARY 2023
Mimi's Rock Corp. is an online dietary supplement and wellness company which market and sells its products under the Dr. Tobias, All Natural Advice and Maritime Naturals brand names. The Dr. Tobias brand features over 30 products, including the top-selling Colon 14-Day Cleanse and the #1 selling Omega 3 Fish Oil on Amazon.com. All Natural Advice and Maritime Naturals products focus on skin and beauty care. Products sold under the All Natural and Maritime Naturals brand names are made in Canada and registered with Health Canada and under the EU Cosmetics Act. All Natural Advice has been featured on BNN as a top selling skincare brand in Canada, and has been rated the #1 Beauty Brand on Amazon Canada for the past four years.
X
CDN $8,100,000
CareRx
BOUGHT DEAL
JANUARY 2023
CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve over 93,000 residents in over 1,600 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.
X
adMare BioInnovations
MONETIZATION PLANNING
OCTOBER 2022
With a wealth of globally-competitive scientific discovery, Canada is primed to lead the life sciences world. To make this a reality, at adMare BioInnovations, we use our scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, robust ecosystems and industry-ready talent — and re-invest our returns back into the Canadian industry to ensure it is sustained for the long-term Our 28 portfolio companies have attracted more than $1.4 billion of investment, have a combined value of over $3 billion, and employ more than 1000 Canadians. As part of our commitment to build talent, we have created the adMare Academy, dedicated to providing the specialized training required to foster the next generation of highly qualified personnel who will drive the growth of Canadian life science companies. The adMare Academy has trained more than 500 alumni – 95% of whom are employed in the Canadian life sciences industry.
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
OCTOBER 2022
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
X
Salus Global
MONETIZATION PLANNING
SEPTEMBER 2022
For more than 11 years, Salus Global Corporation has been recognized as the world leader in helping healthcare organizations achieve better clinical, economic, and operational outcomes. A specialty consulting and implementation firm, we help healthcare organizations improve performance and quality outcomes through increased interprofessional collaboration.
X
CDN $3,500,000
Satellos Bioscience
PUBLIC OFFERING
SEPTEMBER 2022
Satellos is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how muscle disorders are treated.
Satellos' lead program is focused on developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. We believe our unique therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients. To expand our programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment.
X
RxPx
M&A ADVISORY
SEPTEMBER 2022
About RxPx Corp.
In the evolving digital health industry, a newly merged company is on a mission to help healthcare and transform lives. RxMx and Curatio, backed by private equity firm Pemba Capital Partners, have merged to form RxPx.
RxPx is positioned to become the global leader in patient management software for life sciences companies globally. The combined strengths of newly merged RxMx and Curatio will deliver next level solutions to transform the lives of patients, especially those on specialty therapies.
The name RxPx combines Rx for prescription medication and Px for patient experience. With a mission of No Patient Alone, RxPx provides an end to end workflow solution that reduces burden on doctors, and supports patients at scale. The merger comes at a time when health systems are collapsing, pharmaceutical companies are undergoing massive change, and patients are increasingly relying on digital options.
RxPx is used in over 100 countries, available in 15 languages and has been designed specifically for the privacy, security and compliance needs of healthcare. RxMx was started by doctors for doctors to support physician workflows through automated processes that increase speed and access to therapy. Curatio was started by patients for patients as a social health prescription, enabling any healthcare organization to easily deliver private, personalized social support, education, daily coaching and adherence tracking
X
Field Trip Health Ltd.
SPIN-OUT; M&A ADVISORY
AUGUST 2022
About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
About Field Trip Health & Wellness Ltd.
Field Trip Health & Wellness Ltd. is a global leader in psychedelic therapies. With health centres across North America and Europe, along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.
X
US$20,000,000
Medicenna Therapeutics Corp.
PUBLIC OFFERING
AUGUST 2022
Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Superkines.
X
US$75,000,000
Greenbrook TMS
DEBT FINANCING
JULY 2022
Operating through 193 Company-operated treatment centers (including those added through the Acquisition), Greenbrook is a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 840,000 TMS treatments to over 24,000 patients struggling with depression.
X
SteriMax
MONETIZATION PLANNING
JULY 2022
SteriMax Inc. develops, sources, manufactures, markets and distributes essential hospital and retail pharmacy products to the Canadian healthcare market. The company was founded by Mahen (Mike) Acharya, in the late 90’s through a series of strategic alliances.
From inception, SteriMax Inc. has been dedicated to the maintenance, promotion and reinvigoration of niche evidence based pharmaceutical products that are coveted by the Canadian healthcare system but under threat of discontinuation by the companies that originated them. Building on this foundation that included several well-established sterile injectable products, SteriMax has successfully added an array of parenteral products, establishing a formidable portfolio of products that are essential for the Canadian Hospital market. As a committed partner in this segment, SteriMax has placed great emphasis on the reliability and stability of product supply.
Despite our strength in Sterile Injectable products, we have also found unmet needs and opportunity within niche oral solid, nasal spray and ophthalmic products and these have served to expand our presence in the Canadian Retail pharmaceutical sector.
X
Undisclosed Digital Health Company
Advisory
JUNE 2022
X
Appili Therapeutics
MONETIZATION PLANNING
JUNE 2022
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection.
X
CDN$4,500,000
Appili Therapeutics
PUBLIC OFFERING
MAY 2022
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection.
X
US$5,000,000
Virica Biotech
SERIES A FINANCING
MAY 2022
Virica optimizes the manufacturing of viral medicines which allows developers to economically deploy their products at scale. Virica’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate anti-viral defenses in manufacturing cells. Customizable VSE cocktails substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, cell and gene therapies, and anticancer therapies.
X
CDN$3,390,000
Newtopia Inc.
PRIVATE PLACEMENT
APRIL 2022
Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for health insurers. As a provider of whole person care, we prevent, reverse, and slow the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social, and behavioural insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed on the Toronto Stock Exchange and quoted on the OTC Venture Market in the United States (TSXV: NEWU) (OTCQB: NEWUF).
X
CDN$5,678,000
Avivagen Inc.
PRIVATE PLACEMENT
MARCH 2022
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada.
X
Pillar5 Pharma Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2022
Pillar5, based in Arnprior, Ontario, became in independent company in 2009 and is one of the primary North American CDMOs for the production of sterile ophthalmic solutions and for solid dose manufacturing (tablets, capsules, etc.). Pillar5 was the first CDMO to offer multi-dose preservative free manufacturing capabilities for the North American ophthalmic market and offers services ranging from formulation, product manufacturing and custom packaging to technical services.
For information: www.pillar5pharma.com.
X
Searchlight Pharma
MERGER & ACQUISTION ADVISORY, DEBT FINANCING
JANUARY 2022
MONTRÉAL, Jan. 5, 2022 /CNW Telbec/ - Searchlight Pharma Inc. ("Searchlight"), a Canada focused, Montréal-based specialty healthcare company focused on women's health, urogynecology, and urology, announced today that it has completed the acquisition of ERFA Canada 2012 Inc. ("ERFA"), a Montréal-based distributor of niche pharmaceutical products across Canada addressing a range of underserved medical indications.
"We are very excited to announce the acquisition of ERFA and to welcome their high performing team to the Searchlight family," said Mark Nawacki, President & CEO of Searchlight Pharma Inc. "ERFA's portfolio of 23 marketed brands is synergistic with our existing business, and we look forward to continuing ERFA's mission to provide access to important niche products to patients across the country. The combination of Searchlight and ERFA creates a compelling platform with attractive critical mass across products, business operations and infrastructure. We are very well positioned to continue to deliver on our growth strategy while providing dependability and value to Canadian customers and patients."
Searchlight was advised by Bloom Burton Securities Inc. (financial advisory), Ernst & Young LLP (strategy and transactions, tax advisory), and Davies Ward Phillips and Vineberg (legal advisory). ERFA was advised by PricewaterhouseCoopers Corporate Finance Inc. (financial advisory), Raymond Chabot Grant Thornton LLP and Deloitte LLP (tax advisory), and Dunton Rainville (legal advisory).
Details of the transaction were not disclosed.
X
FORUS Therapeutics
MONETIZATION PLANNING
JANUARY 2022
FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. Our mission is to bring solutions to cancer patients, caregivers, physicians and our partners by accelerating unique and important treatments that meaningfully enhance life.
X
US$15,000,000
IMV Inc.
DEBT FINANCING
DECEMBER 2021
IMV Inc. is a clinical-stage pharmaceutical company that has the potential to make history by developing a first-in-class effective T cell-targeted immune therapy for cancer. We have built an unprecedented delivery platform (DPX) that generates targeted immune cells directly into the human body, which produces robust, and sustained capabilities to destroy cancer. DPX is the engine that drives our lead drug candidate, maveropepimut-S (DPX-Survivac), which has successfully completed multiple Phase 1/1b trials, generating best-in-class results in advanced recurrent ovarian cancer and Diffuse Large B Cell Lymphoma (DLBCL).
X
US$200,000,000
Bellus Health
PUBLIC OFFERING
DECEMBER 2021
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of adults with RCC.
X
CDN$7,000,220
Appili Therapeutics
PUBLIC OFFERING
OCTOBER 2021
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Offering”) of units (the “Units”). The Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including iA Private Wealth Inc., Leede Jones Gable Inc., Research Capital Corporation, and Richardson Wealth Limited (collectively with the Lead Agent, the “Agents”) and the Company.
Pursuant to the Offering, the Company issued a total of 8,434,000 Units at a price of $0.83 per Unit for aggregate gross proceeds of $7,000,220. Each Unit is comprised of one Class A common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share (a “Warrant Share”) at an exercise price of $1.10 per Warrant Share until October 14, 2024.
X
US$13,200,000
Greenbrook TMS
BOUGHT DEAL
SEPTEMBER 2021
Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce the closing of its previously-announced public offering (the “Offering”). The Offering was made pursuant to an underwriting agreement entered into among Stifel GMP, Bloom Burton Securities Inc. and Lake Street Capital Markets, LLC (collectively, the “Underwriters”).
Pursuant to the Offering, the Company issued a total of 1,707,750 common shares of the Company (the “Common Shares”) at a price of US$7.75 per Common Share for gross proceeds of approximately US$13.2 million, including 222,750 Common Shares issued pursuant to the full exercise of the Underwriters’ over-allotment option. The Company intends to use the net proceeds from the Offering to fund its previously-announced acquisition of Achieve TMS East, LLC and Achieve TMS Central, LLC and for working capital and general corporate purposes.
The Common Shares were qualified for sale by way of a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated July 22, 2021 (the “Base Shelf Prospectus”) in the United States and Canada. The Prospectus Supplement was also filed with the U.S. Securities and Exchange Commission (the “SEC”) to the Base Shelf Prospectus as part of the Company’s effective registration statement on Form F-10 previously filed under the U.S./Canada multi-jurisdictional disclosure system.
Clarus Securities Inc. and Desjardins Securities Inc. served as independent financial advisors to the Company in connection with the Offering.
X
CDN$25,060,000
Grey Wolf Animal Health Inc.
PRIVATE PLACEMENT
AUGUST 2021
Grey Wolf Animal Health is a specialty animal health company focused on improving the lives and well-being of vets and pets in Canada. Founded in 2015 by Dr. Ian Sandler, our mission is to identify and bring to market products, solutions and services that meet the underserved needs of vets, pets and clinics across Canada.
X
GRO Biosciences
MONETIZATION PLANNING
AUGUST 2021
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at LabCentral in Cambridge, MA — a shared laboratory space for high-potential life sciences and biotechnology startups.
X
Antibe Therapeutics Inc.
MONETIZATION PLANNING
JULY 2021
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development for the treatment of osteoarthritis pain. Additional assets include a safer alternative to opioids for peri-operative pain, and a GI-sparing alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.
X
CDN$13,800,920
Skylight Health Group
BOUGHT DEAL
MAY 2021
Skylight Health Group Inc. (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, is pleased to announce that it has closed its previously announced bought deal offering of 9,857,800 common shares (the "Common Shares", each a "Common Share") in the capital of the Company at a price of C$1.40 per Common Share for aggregate gross proceeds to the Company of C$13,800,920 (the "Offering"), inclusive of the full exercise of the over-allotment option.
The Offering was completed on a bought deal basis and was underwritten by a syndicate of underwriters led by Raymond James Ltd. as sole bookrunner and co-lead underwriter and Stifel GMP as co-lead underwriter on behalf of a syndicate including Beacon Securities Limited, Echelon Wealth Partners Inc., and Bloom Burton Securities Inc. (collectively the “Underwriters").
Skylight Health intends to use the proceeds of the Offering to fund growth initiatives, including executing its M&A strategy, and for general corporate purposes.
X
Green Shield Canada
MONETIZATION PLANNING
MAY 2021
GSC is a health benefits provider. But, as a social enterprise we are more than what we do. Working to make it easier for people to live their healthiest lives is central to who we are.
As a leader in the health benefits industry, we are structured into three core lines of business: group and individual health benefits, and third-party administration solutions.
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
MAY 2021
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
X
CDN$5,750,000
Microbix Biosystems Inc.
PRIVATE PLACEMENT
MAY 2021
MISSISSAUGA, Ontario, May 19, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces it has closed its previously-announced bought-deal public offering (the “Offering”) and concurrent private placement (the “Placement”).
The co-lead bookrunners and underwriters of the Offering, iA Private Wealth Inc. and Bloom Burton Securities Inc. (the “Underwriters”), have purchased the full Offering, including all of the 15% overallotment option, for a total of 9,583,334 units (“Units”), at a price of $0.60 per Unit for aggregate gross proceeds of $5,750,000. The Company also closed its concurrent Placement of 1,916,666 Units for gross proceeds of $1,150,000, also upsized by 15% from the previously announced $1,000,000.
X
CDN$7,250,000
Satellos Bioscience
PRIVATE PLACEMENT
APRIL 2021
iCo Therapeutics Inc. (TSXV: ICO) (OTC: ICOTF) ("iCo" or the "Company") is pleased to announce that it has closed its previously announced private placement (the "Financing") in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act. The completion of the Arrangement will result in the reverse takeover of the Company as defined in the policies of the TSX Venture Exchange ("TSXV") and the resulting entity will continue to operate in the life sciences industry under the name "Satellos Bioscience Inc." (the "Resulting Issuer").
Pursuant to the Financing, the Company issued 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million. Each Subscription Receipt will entitle the holder thereof to receive, upon satisfaction of certain escrow release conditions, including without limitation, the completion of the Arrangement, and without payment of additional consideration, one common share of the Resulting Issuer (a "Resulting Issuer Share"). The proceeds from the Financing have been placed in escrow and, upon satisfaction of the escrow release conditions, will be used for research, development, and general corporate expenses of the Resulting Issuer.
The Resulting Issuer Shares issued in connection with the Financing will be subject to a hold period expiring 4 months and one day from the date of issuance in accordance with applicable Canadian securities laws. Additionally, in connection with the Financing, certain Resulting Issuer Shares issued to former shareholders of Satellos pursuant to the Arrangement will be subject to a lock-up agreement.
The Financing was led by Bloom Burton Securities Inc. and includes Richardson Wealth Ltd.
X
Field Trip Health Ltd.
MONETIZATION PLANNING
JUNE 2021
Field Trip is the global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.
X
Undisclosed Large Pharma
MONETIZATION PLANNING
APRIL 2021
X
CDN$95,000,000
Field Trip Health Ltd.
BOUGHT DEAL
MARCH 2021
TORONTO, March 17, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021, including the full exercise of the underwriters’ over-allotment option (the "Offering"). In connection with the Offering, Field Trip issued 14,661,499 common shares, (“Common Shares”) at a price of C$6.50 per Common Share, for aggregate gross proceeds of $95 million.
X
CDN$40,365,000
Antibe Therapeutics Inc.
BOUGHT DEAL
FEBRUARY 2021
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX:ATE) today announced that it has closed its previously announced bought deal public offering of 6,727,500 units (the “Offered Securities”) in the capital of the Company at a price of C$6.00 per Offered Security (the “Offering Price”) for aggregate gross proceeds to the Company of C$40,365,000 (the “Offering”), which includes the full exercise of the over-allotment option by the underwriters.
Each Offered Security consisted of one common share (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price per Common Share of C$7.50 for a period of 36 months from the closing of the Offering.
X
US$23,004,600
Titan Medical Inc.
BOUGHT DEAL
FEBRUARY 2021
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 8,335,000 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of US $20,004,000 (the “Offering”). Bloom Burton Securities Inc. acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 1,250,250 Units and additional gross proceeds to the Company of US $3,000,600. The aggregate gross proceeds to the Company under the Offering were US $23,004,600.
X
CDN$32,529,992
Medexus Pharmaceuticals Inc.
PUBLIC OFFERING
FEBRUARY 2021
TORONTO, CHICAGO and MONTREAL, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) announced today that it has closed its previously announced bought deal public offering of 4,581,689 units (the “Units”) at a price of $7.10 per Unit for total gross proceeds of approximately $32,529,992 (the “Offering”), including 597,611 Units sold pursuant to the exercise in full of the over-allotment option granted to the Underwriters (as defined herein).
The Offering was led by Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters consisting of Roth Canada, ULC, Bloom Burton Securities Inc. and Mackie Research Capital Corporation (collectively, the “Underwriters”).
X
US$150,000,000
ESSA Pharma Inc.
PUBLIC OFFERING
FEBRUARY 2021
VANCOUVER, BC and HOUSTON, March 4, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the underwriters have exercised their option (the "Option") to purchase an additional 724,637 common shares in the capital of the Company (the "Common Shares"), in connection with the Company's recently completed underwritten public offering of 4,830,918 Common Shares, which closed on February 22, 2021 (the "Offering"). On closing of the Option, the Company will have issued 5,555,555 Common Shares pursuant to the Offering for gross proceeds of approximately $150 million.
X
CDN$7,500,000
Avivagen Inc.
BOUGHT DEAL
FEBRUARY 2021
OTTAWA, ON / Business Wire/– February 16, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announced today that it closed its previously announced offering of 15,000,000 units of the Company (the “Units”) on a “bought deal” basis, at a price of $0.50 per Unit (the “Offering Price”) for aggregate gross proceeds of $7,500,000 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) acted as underwriter for the Offering.
X
CDN$34,303,500
Cybin Inc.
BOUGHT DEAL
JANUARY 2021
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering (the “Offering”), including the exercise of the over-allotment option granted to the Underwriters (as defined herein). In connection with the Offering, the Company issued 15,246,000 units of the Company (the “Units”) at a price of CDN$2.25 per Unit (the “Issue Price”) for aggregate gross proceeds of CDN$34,303,500. The Offering was conducted by Canaccord Genuity (the “Lead Underwriter”), as lead underwriter and sole bookrunner, with Stifel Nicolaus Canada Inc., Eight Capital and Bloom Burton Securities Inc. (together with the Lead Underwriter, the “Underwriters”). To date, the Company has raised approximately CDN$88.8 million.
X
US$11,500,000
Titan Medical Inc.
BOUGHT DEAL
JANUARY 2021
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 6,451,613 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of approximately US $10,000,000.00 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 967,741 Units and additional gross proceeds to the Company of approximately US $1,500,000. The aggregate gross proceeds to the Company under the Offering were approximately US $11,500,000.
X
CDN$20,016,900
Field Trip Health Ltd.
BOUGHT DEAL
JANUARY 2021
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (“Field Trip” or the “Company”) (CSE: FTRP) (OTCBB: FTRPF), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriters' over-allotment option (the "Offering"). In connection with the Offering, the Company issued 4,448,200 units of the Company (the "Units") at a price of CAD$4.50 per Unit, for aggregate gross proceeds of $20,016,900. The Offering was conducted by Stifel GMP (the “Lead Underwriter”), as lead underwriter and sole bookrunner with Canaccord Genuity Corp., Bloom Burton Securities Inc. and Eight Capital forming the syndicate of underwriters (together with the Lead Underwriter, the “Underwriters”).
X
US$30,000,000
Greenbrook TMS
DEBT FINANCING
DECEMBER 2020
December 31, 2020 – Toronto, Ontario – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today that it and its subsidiaries have entered into a credit and security agreement for a US$30 million secured credit facility (the “Credit Facility”) with Oxford Finance LLC (“Oxford”).
X
CDN$74,750,000
MindBeacon Holdings Inc.
INITIAL PUBLIC OFFERING
DECEMBER 2020
TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- MindBeacon Holdings Inc. (“MindBeacon” or the “Company”) (TSX: MBCN) announced today the successful closing of its previously announced initial public offering (the “Offering”) pursuant to which it and TELUS Corporation, 1930339 Ontario Inc., 2451585 Ontario Inc. and 1964998 Ontario Inc. (the “Selling Shareholders”) sold an aggregate of 9,343,750 common shares at a price of $8.00 per share, for total gross proceeds of $74,750,000. The Offering includes the exercise in full by the Underwriters (as defined below) of their over-allotment option to acquire 1,218,750 additional shares of the Company from the Selling Shareholders. The Company received gross proceeds of $65,000,000 and the Selling Shareholders received gross proceeds of $9,750,000.
X
CDN$5,000,000
AceAge
SERIES A FINANCING
DECEMBER 2020
BURLINGTON, ON, Dec. 3, 2020 /CNW/ - AceAge Inc. ("AceAge"), a Canadian healthcare technology company with its innovative medication dispenser, Karie, announced that it has closed a CA $5 million Series A financing round led by Longliv Ventures, a member of the CK Hutchison Holdings Group ("CKHH"), with the participation of a fund managed by the Bloom Burton Investment Group ("Bloom Burton"). Dr Dan Eldar, Managing Director at Longliv Ventures, will join the AceAge Board of Directors. Longliv Ventures Fund, a member of CKHH, focuses on consumer-oriented digital health solutions. CKHH, via its retail division AS Watson, operates the world's largest international health and beauty retailer, with over 15,800 stores in 27 markets worldwide.
X
Green Shield Canada
MONETIZATION PLANNING
DECEMBER 2020
GSC is a health benefits provider. But, as a social enterprise we are more than what we do. Working to make it easier for people to live their healthiest lives is central to who we are.
As a leader in the health benefits industry, we are structured into three core lines of business: group and individual health benefits, and third-party administration solutions.
X
Medicago Inc.
MONETIZATION PLANNING
DECEMBER 2020
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
X
Notch Therapeutics
MONETIZATION PLANNING
OCTOBER 2020
Notch is a leader in the development of cellular therapeutics originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems. The company has unlocked the ability for large-quantity production of T cells and other cells from any source of stem cells to bring best-in-class cell therapy products to thousands of patients. The core of the Notch platform is the Engineered Thymic Niche (ETN), which enables precision control of cell fate during the differentiation and expansion of stem cells, with the potential to generate immunotherapies with decreased variability, increased potency, and engineered improvements. The ETN platform is the first technology that can reliably generate T cells from iPSC-derived progenitor cells using fully defined, non-xenogenic reagents, which has the potential to greatly improve the regulatory, clinical, and commercial attributes for these innovative medicines. The technology was invented in the laboratories of Juan-Carlos Zúñiga-Pflücker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.
X
Undisclosed Large Pharma
MONETIZATION PLANNING
OCTOBER 2020
X
CDN$7,505,000
Newtopia Inc.
Bought Deal
OCTOBER 2020
TORONTO, Oct. 29, 2020 /CNW/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU), a tech-enabled disease prevention company focused on healthy habit change, is pleased to announce that it has closed its previously announced bought deal private placement offering of 7,900,000 units of the Company (the "Units") at a price of $0.95 per Unit (the "Offering Price") for aggregate gross proceeds of $7,505,000 (the "Offering"). The Offering was conducted through a syndicate of underwriters led by Bloom Burton Securities Inc. and included Stifel GMP and INFOR Financial Inc. (collectively, the "Underwriters").
X
Appili Therapeutics Inc.
MONETIZATION PLANNING
SEPTEMBER 2020
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan® (favipiravir) for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection.
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
SEPTEMBER 2020
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
X
GRO Biosciences
MONETIZATION PLANNING
AUGUST 2020
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
X
Atlantic Cancer Research Institute
MONETIZATION PLANNING
AUGUST 2020
The Atlantic Cancer Research Institute (ACRI) is a private, non-profit organization founded in 1998 and situated within the Dr. Georges-L.-Dumont University Hospital Centre in Moncton. ACRI scientists are working with partners in Canada and around the world to impact patient care via the pursuit of research in the area of liquid biopsy and targeted treatment.
We have a research team of over 50 people who have expertise in genomics, proteomics, molecular biology, cell biology, immunology, bioinformatics, pathology, mass spectrometry as well in vitro and in vivo testing. Through its work, ACRI is contributing to the global research effort aimed at combating cancer.
X
US$48,990,000
ESSA Pharma Inc.
PUBLIC OFFERING
JULY 2020
HOUSTON and VANCOUVER, BC, July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 common shares (the "Option"), and the underwriters exercised the Option on July 29, 2020. The proceeds to ESSA from the Offering, including the exercise of the Option, were approximately US$45.0 million after deducting underwriting discounts and commissions (such commission being equal to 6% of the aggregate gross proceeds of the Offering) and other estimated offering expenses. Existing investors participated in the financing along with new investors Pfizer Inc. (NYSE: PFE), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital.
X
iCo Therapeutics
MONETIZATION PLANNING
JULY 2020
iCo is a Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases.
iCo generally focuses on in-licensing drug candidates with a clinical history and re-dose, reformulate and develop drug candidates for the treatment of ocular and infectious diseases. iCo assumes the clinical, regulatory and commercial development activities for its product candidates and advances such candidates along the regulatory and clinical pathway toward commercial approval. iCo believes its approach may reduce the risk, time and cost of developing therapeutics by avoiding some of the uncertainty associated with certain research and pre-clinical stages of drug development.
iCo currently has two in-licensed product candidates in various stages of development: iCo-008 (or for potential use in eotaxin-1 mediated indications, sub-licensed to Alexion Pharmaceuticals Inc., and an oral Amphotericin B delivery system under internal development for potential use in fungal infections).
X
iCo Therapeutics Inc.
MONETIZATION PLANNING
JULY 2020
iCo is a Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases.
iCo generally focuses on in-licensing drug candidates with a clinical history and re-dose, reformulate and develop drug candidates for the treatment of ocular and infectious diseases. iCo assumes the clinical, regulatory and commercial development activities for its product candidates and advances such candidates along the regulatory and clinical pathway toward commercial approval. iCo believes its approach may reduce the risk, time and cost of developing therapeutics by avoiding some of the uncertainty associated with certain research and pre-clinical stages of drug development.
iCo currently has two in-licensed product candidates in various stages of development: iCo-008 (or for potential use in eotaxin-1 mediated indications, sub-licensed to Alexion Pharmaceuticals Inc., and an oral Amphotericin B delivery system under internal development for potential use in fungal infections).
X
CDN$28,750,000
Antibe Therapeutics Inc.
BOUGHT DEAL
JUNE 2020
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit (the "Offering Price") plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the "Offering"). The Offering was made pursuant to an underwriting agreement dated June 15, 2020 with a syndicate of underwriters led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (collectively, the "Underwriters").
X
Precision Biomonitoring
MONETIZATION PLANNING
JUNE 2020
At Precision Biomonitoring we envision a world where we can instantly identify any organism on the spot, anywhere in the world. Founded in 2016, Precision Biomonitoring is a rapidly scaling, commercial stage molecular diagnostics company which provides innovative tools and industry-leading expertise in the molecular detection of organisms. Our proprietary technologies include our commercially available TripleLock™ PCR platform and our lateral flow platform Voilà!™ platform, both which aim to deliver rapid, accurate, on-site environmental, food, animal and human diagnostic testing solutions.
As we continue to grow our human molecular diagnostics business, we look to explore potential partnership opportunities that could enhance our commercial portfolio through product and technology in-licensing, acquisition or other collaboration models.
X
CDN$15,525,000
Appili Therapeutics Inc.
PUBLIC OFFERING
JUNE 2020
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Public Offering”) of units (the “Units”). The Public Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including Mackie Research Capital Corporation, Industrial Alliance Securities Inc., Haywood Securities Inc., and Richardson GMP Limited (collectively with the Lead Agent, the “Agents”) and the Company.
X
CDN$15,000,000
Greenbrook TMS
PUBLIC OFFERING
MAY 2020
TORONTO, ON, May 21, 2020 – Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) is pleased to announce the closing of its previously announced public offering (the “Offering”) of common shares of the Company (the “Offered Shares”). The Offering was made pursuant to an agency agreement (the “Agency Agreement”) entered into among Bloom Burton Securities Inc. and Clarus Securities Inc., as co-lead agents, Canaccord Genuity Corp., Desjardins Securities Inc. and Stifel GMP (collectively, the “Agents”).
X
CDN$56,000,000
adMare BioInnovations
MERGER & ACQUISTION ADVISORY
MARCH 2020
X
GRO Biosciences
MONETIZATION PLANNING
MARCH 2020
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
X
CDN$40,250,000
Medicenna Therapeutics Corp.
PUBLIC OFFERING
MARCH 2020
X
CDN$10,250,000
Appili Therapeutics Inc.
PUBLIC OFFERING
FEBRUARY 2020
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
JANUARY 2020
X
US$116,955,000
Trillium Therapeutics Inc.
Public Offering
JANUARY 2020
X
US$60,000,000
Xenon Pharmaceuticals Inc.
Public Offering
JANUARY 2020
X
Precision NanoSystems Inc.
MONETIZATION PLANNING
DECEMBER 2019
PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world’s leading drug researchers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.
X
Neoleukin Therapeutics
MONETIZATION PLANNING
DECEMBER 2019
X
US$178,000,000
Dahlin Pharma
MERGER & ACQUISTION ADVISORY
DECEMBER 2019
Acquisition of Seroquel XR by Dahlin Pharma and Cheplapharm.
Bloom Burton Securities Inc. acted as advisor to Dahlin Pharma.
X
US$191,700,000
Aurinia Pharmaceuticals
PUBLIC OFFERING
DECEMBER 2019
X
CDN$3,000,000
Klinik Health Ventures Corp.
IPO
DECEMBER 2019
X
CDN$18,000,000
BEACON™
SERIES A FOLLOW-ON
NOVEMBER 2019
X
Kane Biotech Inc.
MONETIZATION PLANNING
OCTOBER 2019
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
X
CDN$6,900,000
Medicenna Therapeutics Corp.
PUBLIC OFFERING
OCTOBER 2019
X
US$79,374,102
Bellus Health
U.S. IPO
SEPTEMBER 2019
X
US$36,000,000
ESSA Pharma Inc.
PUBLIC OFFERING; PRIVATE PLACEMENT
AUGUST 2019
X
US$35,000,000
Titan Medical Inc.
COMMON SHARE PURCHASE AGREEMENT
AUGUST 2019
X
CDN$8,050,000
Antibe Therapeutics Inc.
PUBLIC OFFERING
AUGUST 2019
X
Field Trip Health Ltd.
MONETIZATION PLANNING
JULY 2019
Field Trip is the global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.
X
CDN$15,200,000
Resverlogix Corp.
EQUITY OFFERING
JUNE 2019
X
CDN$50,025,008
HLS Therapeutics Inc.
BOUGHT DEAL
JUNE 2019
X
CDN$30,579,250
Greenbrook TMS
BOUGHT DEAL; PRIVATE PLACEMENT
MAY 2019
X
CDN$5,260,000
Avivagen Inc.
PRIVATE PLACEMENT
MARCH 2019
X
US$28,750,000
Titan Medical Inc.
PUBLIC OFFERING
MARCH 2019
X
CDN$3,586,813
Appili Therapeutics Inc.
PRIVATE PLACEMENT
MARCH 2019
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
FEBRUARY 2019
X
US$110,000,000
Nuvo Pharmaceuticals Inc.
MERGER & ACQUISTION ADVISORY
DECEMBER 2018
X
CDN$4,000,000
Medicenna Therapeutics Corp.
Public Offering
DECEMBER 2018
X
CDN$35,000,000
Bellus Health
EQUITY OFFERING
DECEMBER 2018
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
OCTOBER 2018
X
UP TO CDN$88,000,000
Pediapharm Inc.
Merger & Acquisition Advisory
OCTOBER 2018
X
US$63,000,000
Xenon Pharmaceuticals Inc.
Public Offering
SEPTEMBER 2018
X
CDN$9,150,000
LED Medical Diagnostics Inc.
Private Placement
SEPTEMBER 2018
X
CDN$10,000,000
Hamilton Thorne Ltd.
BOUGHT DEAL; PRIVATE PLACEMENT
AUGUST 2018
X
US$19,198,935
Titan Medical Inc.
PUBLIC OFFERING
AUGUST 2018
X
CDN$16,000,000
Mimi's Rock
DEBT FINANCING
JULY 2018
X
CDN$17,400,000
Mimi's Rock
PRIVATE PLACEMENT
JULY 2018
X
U.S. R&D Institute
MONETIZATION PLANNING
JUNE 2018
X
US$20,000,000
Greenbrook TMS
PRIVATE PLACEMENT
JUNE 2018
X
Multinational Pharmaceutical Company
MONETIZATION PLANNING
MAY 2018
X
Multinational Pharmaceutical Company
MONETIZATION PLANNING
MAY 2018
X
CDN$6,184,647
Kneat Software
PRIVATE PLACEMENT
APRIL 2018
X
CDN$10,139,988
Titan Medical Inc.
PUBLIC OFFERING
APRIL 2018
X
CDN$27,797,275
Sunniva Inc.
BOUGHT DEAL; PUBLIC OFFERING
MARCH 2018
X
CDN$14,375,000
Immunovaccine Inc.
BOUGHT DEAL
FEBRUARY 2018
X
Satellos Bioscience Inc.
Company Creation
2018
Satellos is a private, Canadian-based regenerative medicine company formed in 2018. The initial focus of the company is muscle regeneration, with a lead program in Duchenne Muscular Dystrophy.
X
US$26,040,000
ESSA Pharma Inc.
PUBLIC OFFERING
JANUARY 2018
X
Precision Nutrition
MERGER & ACQUISTION ADVISORY
DECEMBER 2017
X
CDN$20,000,000
Bellus Health
PUBLIC EQUITY OFFERING
DECEMBER 2017
X
CDN$23,000,000
Titan Medical Inc.
PUBLIC OFFERING
DECEMBER 2017
X
CDN$4,000,000
Avivagen Inc.
PRIVATE PLACEMENT
NOVEMBER 2017
X
CDN$8,925,000
Titan Medical Inc.
PUBLIC OFFERING
JUNE 2017
X
CDN$4,983,000
Antibe Therapeutics Inc.
PUBLIC OFFERING
JUNE 2017
X
CDN$10,000,000
Resverlogix Corp.
PUBLIC OFFERING
JUNE 2017
X
TechAlliance of Southwestern Ontario
MONETIZATION PLANNING
APRIL 2017
X
EUR €13,900,000
Hamilton Thorne Ltd.
MERGER & ACQUISTION ADVISORY
APRIL 2017
X
CAD $12,500,000
Hamilton Thorne Ltd.
PRIVATE PLACEMENT
APRIL 2017
X
Weed MD
MONETIZATION PLANNING
MAY 2017
X
Alberta Innovates
MONETIZATION PLANNING
MAY 2017
X
NeuPath Health
Company Creation
2017
NeuPath is Canada's largest provider of chronic pain services. Through their network and brands, NeuPath is constantly expanding the scope of their services to serve communities.
X
CDN$7,500,000
Titan Medical Inc.
PUBLIC OFFERING
MARCH 2017
X
Alberta Innovates
MONETIZATION PLANNING
MARCH 2017
X
Aquinox Pharmaceuticals Inc.
MONETIZATION PLANNING
MARCH 2017
X
CAD $4,000,000
Medicenna Therapeutics Corp.
Private Placement
March 2017
X
CAD $14,400,000
LED Medical Diagnostics Inc.
Private Placement
February 2017
X
US $10,250,000
LED Medical Diagnostics Inc.
MERGER & ACQUISITION ADVISORY
FEBRUARY 2017
X
CAD $100,050,000
Knight Therapeutics Inc.
Bought Deal
December 2016
X
CAD $10,000,000
Medicenna Therapeutics Corp.
Private Placement
December 2016
X
CAD $5,004,000
CannaRoyalty Corp.
Private Placement
OCTOBER 2016
X
CAD $10,000,000
Newtopia Inc.
Series A Financing
OCTOBER 2016
X
CAD $11,428,000
Titan Medical Inc.
Public Offering
OCTOBER 2016
X
CAD $6,000,000
Red Leaf Medical Inc.
MERGER & ACQUISITION ADVISORY
SEPTEMBER 2016
X
Bellus Health Inc.
MONETIZATION PLANNING
SEPTEMBER 2016
X
Clementia Pharmaceuticals
MONETIZATION PLANNING
SEPTEMBER 2016
X
Response Biomedical Corp.
MERGER & ACQUISITION ADVISORY
AUGUST 2016
X
US $107,000,000
Noden Pharma Inc.
Private Placement
JULY 2016
X
Noden Pharma Inc.
MERGER & ACQUISITION ADVISORY
JULY 2016
X
Medicago Inc.
MONETIZATION PLANNING
JULY 2016
X
CAD $230,000,000
Knight Therapeutics Inc
Bought Deal
JUNE 2016
X
CAD $15,000,000
Titan Medical Inc.
Public Offering
APRIL 2016
X
Canadian Public Pharmaceutical Company
Valuation Opinion
MARCH 2016
X
CAD $82,980,000
Nuvo Reserach Inc.
Fairness Opinion
MARCH 2016
X
CAD $12,080,000
Titan Medical Inc.
Private Offering
FEBRUARY 2016
X
Medicenna Therapeutics Corp.
MONETIZATION PLANNING
FEBRUARY 2016
X
US $148,000,000
Tribute Pharmaceuticals Canada Inc.
Merger & Acquisition Advisory
FEBRUARY 2016
X
Canadian Public Biotech Company
MERGER & ACQUISITION ADVISORY
JANUARY 2016
X
CAD $12,300,000
INTEGA Skin Sciences Inc.
Debt
JANUARY 2016
X
US $15,000,000
ESSA Pharma Inc.
Private Placement
JANUARY 2016
X
Appili Therapeutics Inc.
Company Creation
2015
Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this critical disease space.
X
Grey Wolf Animal Health Inc.
Company Creation
2015
Grey Wolf Animal Health is a specialty animal health company focused on improving the lives and well-being of vets and pets in Canada and abroad. Founded in 2015 by Dr. Ian Sandler, their mission is to identify and bring to market products, solutions and services that meet the underserved needs of vets, pets and clinics across Canada.
X
Triumvira Immunologics Inc.
Company Creation
2015
Triumvira is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
X
Medicago Inc.
Monetization Planning
NOVEMBER 2015
X
CAD $2,120,000
LED Medical Diagnostics Inc.
Public Offering
NOVEMBER 2015
X
CAD $47,000,000
Alveda Pharmaceuticals Inc.
Merger & Acquisition Advisory
NOVEMBER 2015
X
Arthritis Innovation Corporation
Valuation Opinion
October 2015
X
US $200,000,000
HLS Therapeutics Inc.
Private Placement
AUGUST 2015
X
US $185,000,000
HLS Therapeutics Inc.
Syndicated Loan
AUGUST 2015
X
Exerkine Corporation
Merger & Aquisition Advisory
AUGUST 2015
X
CAD $1,590,000
Diagnos Inc.
Private Placement
JULY 2015
X
CAD $2,680,000
Agility Health Inc.
Public Offering
JUNE 2015
X
CAD $4,020,000
Medicure Inc.
Bought Deal; Private Placement
JUNE 2015
X
CAD $12,500,000
Tribute Pharmaceuticals Canada Inc.
Private Placement
JUNE 2015
X
CAD $25,000,000
Medical Futures Inc.
Merger & Acquisition Advisory
JUNE 2015
X
CAD $12,000,000
Tribute Pharmaceuticals Canada Inc.
Raising Capital & Financing
MAY 2016
X
US $55,150,000
Trillium Therapeutics Inc.
Public Offering
APRIL 2015
X
CAD $24,010,000
Profound Medical Corp.
Private Placement
APRIL 2015
X
CAD $5,500,000
Pediapharm Inc.
Private Placement
MARCH 2015
X
CAD $27,370,000
CRH Medical Corporation
Bought Deal
MARCH 2015
X
Qing Bile Therapeutics Inc.
Company Creation
2015
Qing Bile Therapeutics is a preclinical stage, private Canadian biotechnology company founded in 2015 based on research from Dr. Victor Ling’s laboratory at the University of British Columbia and BC Cancer Agency. Qing Bile has identified tetrahydroxylated bile acids (THBAs) to treat cholestatic and metabolic diseases with high unmet need.
X
Ontario Academic Institution
Monetization Planning
JANUARY 2015
X
Xenon Pharmaceuticals Inc.
Monetization Planning
JANUARY 2015
X
US $12,000,000
ESSA Pharma Inc.
Private Placement
JANUARY 2015
X
Pharmascience Inc.
Monetization Planning
JANUARY 2015
X
CAD $100,000,000
Knight Therapeutics Inc.
Bought Deal
DECEMBER 2014
X
US $52,000,000
CRH Medical Corporation
Debt
DECEMBER 2014
X
US $73,200,000
CRH Medical Corporation
Merger & Acquisition Advisory
DECEMBER 2014
X
CAD $1,350,000
ESSA Pharma Inc.
Private Placement
OCTOBER 2014
X
US $45,000,000
Nuvo Research Inc.
Merger & Acquisition Advisory
OCTOBER 2014
X
iCo Therapeutics Inc.
Monetization Planning
OCTOBER 2014
X
TEC Edmonton
Monetization Planning
OCTOBER 2014
X
CAD $5,766,100
Bioniche Life Sciences Inc.
Private Placement
SEPTEMBER 2014
X
CAD $3,400,000
ESSA Pharma Inc.
Private Placement
JULY 2014
X
CAD $30,026,500
Tribute Pharmaceuticals Inc.
Public Offering
JULY 2014
X
Warnex Inc.
MERGER & ACQUISITION ADVISORY
MAY 2014
X
Plantform Corporation
MONETIZATION PLANNING
MAY 2014
X
McMaster University Faculty of Health Sciences
MONETIZATION PLANNING
MAY 2014
X
CAD $180,075,000
Knight Therapeutics Inc.
Private Placement
APRIL 2014
X
CAD $3,400,000
Agility Health Inc.
Private Placement
APRIL 2014
X
Antibe Therapeutics Inc.
MONETIZATION PLANNING
APRIL 2014
X
CAD $3,130,000
Nuvo Research Inc.
Private Placement
APRIL 2014
X
Pediapharm Inc.
Monetization Planning
APRIL 2014
X
CPDC
Monetization Planning
MARCH 2014
X
CAD $3,020,000
Antibe Therapeutics Inc.
Raising Capital & Financing
MARCH 2013
X
CAD $3,100,000
Nuvo Pharmaceuticals Inc.
Private Placement
MARCH 2014
X
CAD $3,000,000
Antibe Therapeutics Inc.
Private Placement
MARCH 2014
X
Bioniche Life Sciences Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2014
X
Trillium Therapeutics Inc.
MONETIZATION PLANNING
MARCH 2014
X
Xenon Pharmaceuticals Inc.
Monetization Planning
FEBRUARY 2014
X
CAD $7,530,000
Triton Pharma Inc.
Mergers & Acquisition Advisory
JANUARY 2014
X
CAD $33,000,000
Stem Cell Therapeutics Corp.
Private Placement
DECEMBER 2013
X
Sirona Biochem Corp.
MONETIZATION PLANNING
OCTOBER 2013
X
Approx. CAD $17,000,000
STI Technologies Ltd.
Private Equity Investment
SEPTEMBER 2013
X
CAD $9,804,500
Bioniche Life Sciences Inc.
Public Offering
SEPTEMBER 2013
X
Up to CAD $4,000,000
Response Biomedical Corp.
Private Placement
SEPTEMBER 2013
X
Approx. CAD $357,000,000
Medicago Inc.
MERGER & ACQUISITION ADVISORY
SEPTEMBER 2013
X
CIMTEC
MONETIZATION PLANNING
SEPTEMBER 2013
X
Aquinox Pharmaceuticals Inc.
MONETIZATION PLANNING
SEPTEMBER 2013
X
US $6,000,000
Tribute Pharmaceuticals Inc.
Debt
August 2013
X
Approx. CAD $13,000,000
Thallion Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
August 2013
X
CAD $3,155,100
Antibe Therapeutics Inc.
Initial Public Offering
JUNE 2013
X
CAD $3,379,520
iCo Therapeutics Inc.
Overnight Offering
MAY 2013
X
CAD $40,000,000
Trimel Pharmaceuticals Corp.
Public Offering
APRIL 2013
X
CAD $3,100,000
Stem Cell Therapeutics Corp.
Public Offering
MARCH 2013
X
Victhom Human Bionics Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2013
X
Tekmira Pharmaceuticals
MONETIZATION PLANNING
JANUARY 2013
X
CRH Medical Corp.
MONETIZATION PLANNING
JANUARY 2013
X
CAD $12,500,000
Agility Health Inc.
Private Placement
DECEMBER 2012
X
Approx. US 510,000,000
YM BioSciences Inc.
MERGER & ACQUISITION ADVISORY
DECEMBER 2012
X
Ontario Institute for Cancer Research
MONETIZATION PLANNING
DECEMBER 2012
X
Warnex Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2012
X
CML Healthcare Inc.
MONETIZATION PLANNING
OCTOBER 2012
X
US $7,500,000
Trimel Pharmaceuticals Corp.
Venture debt
JULY 2012
X
CAD $2,550,000
iCo Therapeutics Inc.
Overnight Offering
JULY 2012
X
Pharmagap Inc.
MERGER & ACQUISITION ADVISORY
JULY 2012
X
Bellus Health Inc.
MONETIZATION PLANNING
JUNE 2012
X
Sirona Biochem Corp.
MONETIZATION PLANNING
JUNE 2012
X
Canadian Public Biotechnology Company
MONETIZATION PLANNING
JUNE 2012
X
CAD $8,000,000
Nuvo Pharmaceuticals Inc.
Secured Debt
MAY 2012
X
US $6,000,000
Stellar Pharmaceuticals Inc.
Secured Debt
MAY 2012
X
Patient Home Monitoring Corp.
MONETIZATION PLANNING
APRIL 2012
X
Antibe Therapeutics Inc.
MONETIZATION PLANNING
JANUARY 2012
X
CAD $448,231
Microbix Biosystems Inc.
Public Offering
DECEMBER 2011
X
Approx. CAD $10,000,000
Stellar Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
DECEMBER 2011
X
CAD $3,520,000
Botaneco Inc.
Private Placement
OCTOBER 2011
X
CAD $10,000,000
Allon Therapeutics Inc.
Public Offering
OCTOBER 2011
X
Advitech Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2011
X
CAD $25,000,000
Medicago Inc.
Private Placement
SEPTEMBER 2011
X
CAD $2,200,000
Lorus Therapeutics Inc.
Public Offering
AUGUST 2011
X
CAD $12,600,000
Resverlogix Corp.
Overnight Offering
JUNE 2011
X
Nuvo Pharmaceuticals Inc.
MONETIZATION PLANNING
JUNE 2011
X
CAD $717,500
Microbix Biosystems Inc.
Private Placement
APRIL 2011
X
Miraculins Inc.
MONETIZATION PLANNING
APRIL 2011
X
CAD $17,399,976
Medicago Inc.
Overnight Offering
MARCH 2011
X
CAD $2,000,000
Stem Cell Therapeutics Corp.
Overnight Offering
MARCH 2011
X
CAD $40,250,000
Paladin Labs Inc.
Bought Deal
FEBRUARY 2011
X
CAD $1,808,866
Ventripoint Inc.
Private Placement
JANUARY 2011
X
CAD $46,000,000
YM Biosciences Inc.
Public Offering
DECEMBER 2010
X
CAD$ 5,000,000
Agility Health Inc.
Term Debt Financing
DECEMBER 2010
X
CAD $28,777,600
Oncolytics Biotech Inc.
Bought Deal
OCTOBER 2010
X
CAD $7,465,100
ImmunoVaccine Inc.
Public Offering
SEPTEMBER 2010
X
CAD $7,500,000
Medicago Inc.
Overnight Offering
AUGUST 2010
X
Miraculins Inc.
MERGER & ACQUISITION ADVISORY
AUGUST 2010
X
CAD $10,000,000
Resverlogix Corp.
Overnight Offering
JUNE 2010
X
CAD $5,000,000
Patient Home Monitoring Corp.
Equity Line
JUNE 2010
X
CAD $9,200,000
Resverlogix Corp.
Overnight Offering
JUNE 2010
X
CAD $4,500,000
Patient Home Monitoring Corp.
Private Placement
JUNE 2010
X
Patient Home Monitoring Corp.
MERGER & ACQUISITION ADVISORY
JUNE 2010
X
Approx. CAD $7,000,000
DiaMedica Inc.
MERGER & ACQUISITION ADVISORY
JUNE 2010
X
Cipher Pharmaceuticals Inc.
MONETIZATION PLANNING
JUNE 2010
X
Medicago Inc.
MONETIZATION PLANNING
JUNE 2010
X
CAD $10,000,000
Medicago Inc.
Equity Line
MAY 2010
X
US $17,500,000
YM Biosciences Inc.
Registered Direct Offering
MARCH 2010
X
Conjuchem LLC
MERGER & ACQUISITION ADVISORY
MARCH 2010
X
Approx. CAD $12,500,000
YM Biosciences Inc.
MERGER & ACQUISITION ADVISORY
FEBRUARY 2010
X
CAD $8,000,000
Resverlogix Corp.
Private Placement
JANUARY 2010
X
Medicure Inc.
MERGER & ACQUISITION ADVISORY
JANUARY 2010
X
CAD $25,000,000
LaboPharm Inc.
Equity Line
NOVEMBER 2009
X
CAD $11,592,000
Medicago Inc.
Bought Deal
NOVEMBER 2009
X
US $14,662,500
Oncolytics Biotech Inc.
Overnight Offering
NOVEMBER 2009
X
CAD $750,000
Patient Home Monitoring Corp.
Private Placement
OCTOBER 2009
X
CAD $1,500,000
Chemaphor Inc.
Private Placement
APRIL 2009
X
DRM Ventures Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2009
X
CAD $500,000
Med BioGene Inc.
Private Placement
SEPTEMBER 2009
X
Bradmer Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
JULY 2009
X
CDN$58,700,000
Paladin Labs Inc.
Bought Deal
JUNE 2009
X
Med BioGene Inc.
MERGER & ACQUISITION ADVISORY
June 2009
X
CDN$380,000
Chemaphor Inc.
Private Placement
APRIL 2009
